HER2-positive Breast Cancer Clinical Trials in Nanjing, Jiangsu
4 recruitingNanjing, Jiangsu, China
Showing 1–4 of 4 trials
Recruiting
Phase 3
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.1,450 enrolled2 locationsNCT06830889
Recruiting
Phase 3
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.544 enrolled77 locationsNCT07043725
Recruiting
Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients
Breast CancerHER2-positive Breast CancerNeoadjuvant+1 more
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT06479460
Recruiting
Phase 2
Pyrotinib in Women With High-risk in Early Stage Breast Cancer
HER2-positive Breast Cancer
The First Affiliated Hospital with Nanjing Medical University188 enrolled1 locationNCT05834764